Comparison of clinical efficacy of entecavir antiviral 2 decompensated liver cirrhosis and compensatory phase patients with chronichepatitis B

Objective To study entecavir decompensated cirrhosis and decompensated differences in the treatment of chronic hepatitis B patients, provide proper guidance for the clinical treatment of patients with hepatitis B cirrhosis and different stages. Method Randomly selected our hospital patients with decompensated cirrhosis 20 cases, 18 cases of patients with compensated cirrhosis and chronic hepatitis B patients with newly diagnosed 38 cases, three groups of patients were treated with entecavir antiviral treatment, and follow-up observation. Compared the changes of three groups of patients before and after treatment alanine aminotransferase(ALT), aspartate aminotransferase(AST), hepatitis B virus e antigen(HBeAg), HBV DNA quantitative, cholinesterase(CHE), serum total bilirubin(TBIL), serum albumin(ALB) and other indicators. Result Three groups of patients before treatment difference of indicators had no significant(P 0.05). Before each indicator and treatment after treatment, ALT, AST, HBV DNA, TBIL levels showed a clear downward trend, and the difference between before and after treatment was significant(P0.05) in each group; HBeAg, CHE, ALB levels before treatment comparison showed a clear upward trend, the difference was significant(P0.05); after treatment three groups indexes showed no significant difference(P 0.05). Conclusion The clinical entecavir decompensated cirrhosis and decompensated chronic hepatitis B have better recovery of liver function, reduce viral load effect, and for the treatment of liver cirrhosis significant difference.